Fig. 4: Somatic mutations and copy number alterations identified by Memorial Sloan Kettering Mutation Profiling of Actionable Cancer Targets next-generation sequencing assay in 37 primary triple-negative breast carcinomas by PD-L1 status of stromal tumor-infiltrating immune cells. | Modern Pathology

Fig. 4: Somatic mutations and copy number alterations identified by Memorial Sloan Kettering Mutation Profiling of Actionable Cancer Targets next-generation sequencing assay in 37 primary triple-negative breast carcinomas by PD-L1 status of stromal tumor-infiltrating immune cells.

From: Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma

Fig. 4

Cases are represented in columns, and genes are displayed in rows. Alteration types are color-coded according the legend. Somatic mutations in CBFB were significantly associated with PD-L1-negative stromal tumor-infiltrating immune cells in primary triple-negative breast carcinoma on univariate analysis with Fisher exact test (p = 0.03), but no longer significant after adjusting for multiple comparisons (p = 0.32). Values written in red denote significant p < 0.05.

Back to article page